PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Status:
Active, not recruiting
Trial end date:
2025-04-09
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991
given with cetuximab and evaluated the side effects of the combination.